About: Prise en charge des exacerbations : de la ville à l’hôpital

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prise en charge des exacerbations : de la ville à l’hôpital Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Prise en charge des exacerbations : de la ville à l’hôpital
Creator	Brinchault, Graziella Desrues, Benoît Jouneau, Stéphane
Source	Elsevier; Medline; PMC
abstract	The Société de pneumologie de langue française defines acute exacerbation of chronic obstructive pulmonary disease (AE COPD) as an increase in daily respiratory symptoms, basically duration ≥ 48h or need for treatment adjustment. Etiology of EA COPD are mainly infectious, viral (rhinovirus, influenzae or parainfluenzae virus, coronavirus, adenovirus and respiratory syncytial virus) or bacterial (Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis). Pollutant exposure can also lead to AE COPD, such as NO(2), SO(2), ozone or particulates (PM10 and PM2.5). In 30% the etiology remains unknown. Differential diagnoses of AE COPD include infectious pneumonia, pneumothorax, acute heart failure and pulmonary embolism. Presences of signs of severity impose hospitalization: signs of respiratory distress, shock, acute confusion but also fragile patients, insufficient home support or absence of response to initial treatment. AE COPD treatments consist on increase in bronchodilators, chest physiotherapy, and antibiotics if sputum is frankly purulent. Systemic corticosteroids should not be systematic. Recommended dose is 0.5 mg/kg on short course (5–7 days). During hospitalization, oxygen supplementation and thromboprophylaxis could be prescribed. The main interest in non-invasive ventilation is persistent hypercapnia despite optimal medical management. During ambulatory management or hospitalization, clinical assessment at 48–72 h is mandatory.
has issue date	2014-10-22(xsd:dateTime)
bibo:doi	10.1016/j.lpm.2014.03.034
bibo:pmid	25451635
has license	no-cc
sha1sum (hex)	9d088fb91d7987433e75980437e0d8726915fef5
schema:url	https://doi.org/10.1016/j.lpm.2014.03.034
resource representing a document's title	Prise en charge des exacerbations : de la ville à l’hôpital
has PubMed Central identifier	PMC7118899
has PubMed identifier	25451635
schema:publication	Presse Med
resource representing a document's body	covid:9d088fb91d7987433e75980437e0d8726915fef5#body_text
is schema:about of	named entity 'MANAGEMENT' named entity 'DES' named entity 'KEY' named entity 'PRIMARY CARE' named entity 'la ville' named entity 'la 6' named entity 'VNI' named entity 'il faut savoir' named entity 'H. influenzae' named entity 'P. aeruginosa' named entity 'suffisante' named entity 'prednisolone' named entity 'auscultation' named entity 'tumor necrosis factor' named entity 'Il faut savoir' named entity 'Haemophilus influenzae' named entity 'IL-8' named entity 'leucocytes' named entity 'interleukines' named entity 'avantages' named entity 'anticoagulation' named entity 'prednisone' named entity 'prednisolone' named entity 'permet' named entity 'IL-8' named entity 'VNI' named entity 'Elle' named entity 'purulent' named entity 'TNFa' named entity 'prednisone' named entity 'S. aureus' named entity 'VNI' named entity 'VNI' named entity 'S. pneumoniae' named entity 'rhume' named entity 'P. aeruginosa' named entity 'hypercapnia' named entity 'la modification' named entity 'IL-6' named entity 'VNI' named entity 'oxygen supplementation' named entity 'VNI' named entity 'Pseudomonas aeruginosa' named entity 'NFS' named entity 'Elle' named entity 'Elle' named entity 'mise en place' named entity 'M. catarrhalis' named entity 'dont' named entity 'mois' named entity 'VEMS' named entity 'anticoagulation' named entity 'permet' named entity 'ozone' named entity 'Celle' named entity 'Staphylococcus aureus' named entity 'NT-proBNP' named entity 'oxygène' named entity 'fluoroquinolone' named entity 'S. pneumoniae' named entity 'fluoroquinolones' named entity 'Moraxella catarrhalis' named entity 'purulence' named entity 'Elle' named entity 'mois' named entity 'hypertension' named entity 'Streptococcus pneumoniae' named entity 'purulent' named entity 'Cette' named entity 'France' named entity 'Elle' named entity 'la 4' named entity 'ECG' named entity 'ipratropium' named entity 'H. influenzae' named entity 'PRADO' named entity 'IL-6' named entity 'thromboprophylaxis' named entity 'PM10'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software